Time of the First Antiretroviral Treatment (ART) Default and Factors Associated to Early ART Default in the Test and Treat Context: Evidence from the West region of Cameroon

Download Article

DOI: 10.21522/TIJPH.2013.10.02.Art018

Authors : Fabrice Djouma Nembot, Edouard Katayi Tshimwanga, Mboh Khan Eveline, Ismaila Esa, Walters Kum, Agbornkwai Nyenty Agbor, Jerome Ateudjieu


Antiretroviral Treatment (ART) retention continues to be a challenge in Sub-Saharan Africa. Understanding factors that contribute to default at the early stage of ART can contribute to avoid poor treatment outcomes. We conducted a retrospective cross-sectional study on adult patients who initiated ART treatment between October 2019 and September 2020 in 25 health facilities in the West region of Cameroon. Early ART default was defined as having default within the first three months of treatment. The mean age of the 2219 clients included in the analysis was 36.8 (SD:13.4), and 838 (36.5%) were male. The median time to the first ART default of the 629 (28.3%) participants who experienced at least one ART default within 12 months after their ART initiation was 5 months, and 41.2% of those defaults occurred within the first three months of ART. Male gender (AOR =1.3; 95%CI:1.1-1.7) and good health at initiation (AOR =1.7; 95%CI:1.3-2.2) were associated with a high risk of early default; while being followed up in a private facility (AOR =0.3; 95%CI:0.2-0.6) were associated with less risk of early default. The ART default at the early stage of HIV care is high in the West region of Cameroon and more frequent in the male gender and in patients with apparent good health at the time of ART initiation. Interventions should be identified and implemented to ensure continuity of ART treatment especially in males, in clients with good health at the time of ART initiation, and in clients on care in public health facilities.

Keywords: Antiretroviral Treatment, Cameroon, Early default, Test and treat.


[1] UNAIDS 2020. Global HIV & AIDS statistics— Fact sheet [Internet]. 2021 [cited 2021 Nov 23]. Available from: https://www.unaids.org/en/resources/fact-sheet.

[2] 90-90-90: An ambitious treatment target to help end the AIDS epidemic. :40.

[3] Mugavero MJ, Lin H-Y, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. Missed Visits and Mortality in Patients Establishing Initial Outpatient HIV Treatment. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009 Jan 15;48(2):248–56.

[4] Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS Res Hum Retroviruses. 2011 Jul;27(7):751–8.

[5] Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc. 2018;21(2): e25084.

[6] Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013. J Acquir Immune Defic Syndr 1999. 2015 May 1;69(1):98–108.

[7] Carlos S, Burgueño E, Ndarabu A, Reina G, Lopez-del Burgo C, Osorio A, et al. Predictors of retention in the prospective HIV prevention OKAPI cohort in Kinshasa. Sci Rep. 2021 Mar 8;11(1):5431.

[8] Mugavero MJ, Lin H-Y, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009 Jan 15;48(2):248–56.

[9] Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012 Sep 4;157(5):325–35.

[10] Ulett KB, Willig JH, Lin H-Y, Routman JS, Abroms S, Allison J, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDs. 2009 Jan;23(1):41–9.

[11] Zhang Y, Dou Z, Sun K, Ma Y, Chen RY, Bulterys M, et al. Association between missed early visits and mortality among patients of china national free antiretroviral treatment cohort. J Acquir Immune Defic Syndr 1999. 2012 May 1;60(1):59–67.

[12] Nijhawan AE, Liang Y, Vysyaraju K, Muñoz J, Ketchum N, Saber J, et al. Missed Initial Medical Visits: Predictors, Timing, and Implications for Retention in HIV Care. AIDS Patient Care STDs. 2017 May;31(5):213–21.

[13] Digital N, Strategic H. The 2020 - 2024 national digital health strategic plan 1. 2020.

[14] Prevent HIV, test and treat all who support for country’s impact.

[15] Operational guidelines for the implementation of the “test and treat” strategy in Cameroon [Internet]. [cited 2021 Dec 23]. Available from: https://differentiatedservicedelivery.org/Portals/0/adam/Content/4PguUuL3dU2mjDICEGsJFQ/File/Cameroon.pdf.

[16] Choi J, Dekkers OM, le Cessie S. A comparison of different methods to handle missing data in the context of propensity score analysis. Eur J Epidemiol. 2019 Jan 15;34(1):23–36.

[17] Deribe K, Hailekiros F, Biadgilign S, Amberbir A, Beyene BK. Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia. Trop Med Int Health TM IH. 2008 Mar;13(3):328–33.

[18] Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment Interruption in a Primary Care Antiretroviral Therapy Program in South Africa: Cohort Analysis of Trends and Risk Factors. JAIDS J Acquir Immune Defic Syndr. 2010 Nov 1;55(3): e17.

[19] Mody A, Glidden DV, Eshun-Wilson I, Sikombe K, Simbeza S, Mukamba N, et al. Longitudinal Care Cascade Outcomes Among People Eligible for Antiretroviral Therapy Who Are Newly Linking to Care in Zambia: A Multistate Analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Dec 17;71(10): e561–70.

[20] Hall HI, Tang T, Westfall AO, Mugavero MJ. HIV Care Visits and Time to Viral Suppression, 19 U.S. Jurisdictions, and Implications for Treatment, Prevention, and the National HIV/AIDS Strategy. Plos One. 2013 Dec 31;8(12): e84318.

[21] Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003 Oct 15;37(8):1112–8.

[22] Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic. J Acquir Immune Defic Syndr 1999. 2007 Jan 1;44(1):30–7.

[23] Mugavero MJ, Amico KR, Westfall AO, Crane HM, Zinski A, Willig JH, et al. Early Retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr 1999. 2012 Jan 1;59(1):86–93.

[24] Ridgeway K, Dulli LS, Murray KR, Silverstein H, Santo LD, Olsen P, et al. Interventions to improve antiretroviral therapy adherence among adolescents in low- and middle-income countries: A systematic review of the literature. Plos One. 2018 Jan 2;13(1): e0189770.

[25] Mbuagbaw L, Hajizadeh A, Wang A, Mertz D, Lawson DO, Smieja M, et al. Overview of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral therapy and retention in care for people living with HIV: Part 1. BMJ Open [Internet]. 2020 Sep;10(9). Available from: /pmc/articles/PMC7513605/.

[26]           Taylor-Smith K, Tweya H, Harries A, Schoutene E, Jahn A. Gender differences in Retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J [Internet]. 2010 [cited 2021 Dec 24];22(2). Available from: https://www.ajol.info/index.php/mmj/article/view/58794.

[27] Takarinda KC, Harries AD, Shiraishi RW, Mutasa-Apollo T, Abdul-Quader A, Mugurungi O. Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007–2010. Int J Infect Dis. 2015 Jan 1; 30:98–105.

[28] Benson C, Wang X, Dunn KJ, Li N, Mesana L, Lai J, et al. Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US. AIDS Behav. 2020 Dec 1;24(12):3562–73.

[29] Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011 Oct 12;8(4):277.

[30] Badenhorst DHS, Westhuizen CA van der, Britz E, Burger MC, Ferreira N. Lost to follow-up: Challenges to conducting orthopaedic research in South Africa. S Afr Med J. 2018 Oct 26;108(11):917–21.

[31] Dessie G, Wagnew F, Mulugeta H, Amare D, Jara D, Leshargie CT, et al. The effect of disclosure on adherence to antiretroviral therapy among adults living with HIV in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2019 Jun 17;19(1):528.